You are here: Industry Insights > BioVaxys

News List

BioVaxys Begins Toxicity Study Ahead of CoviDTH IND Submission prnasia
October 13, 2021
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that it has started its planned in vivo animal toxicology study of CoviDTH in parallel with the preparation of an IND submission.
BioVaxys Prepares for Groundbreaking Study on reduced ACE2 binding capabilities of Hapten-modified SARS-CoV-2 proteins prnasia
September 28, 2021
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys" or "Company"), announced today that it has initiated what could be a scientifically groundbreaking study...
BioVaxys Bioproduction Partner WuXi Biologics Completes Synthesis Of Recombinant SARS-CoV-2 s-proteins for BVX-0320 and CoviDTH Programs prnasia
September 23, 2021
BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) ("BioVaxys"), announced today that global CDMO partner WuXi Biologics, has completed the synthesis of recombinant SARS-CoV-2 s-protein for BVX-0320...
Clinical Trial Affirms CoviDTH Diagnostic Approach to screen for T cell-mediated immune response to SARS-CoV-2 is safe and effective in humans prnasia
August 04, 2021
BioVaxys Technology Corp. is pleased to announce that Immunologist Yvelise Barrios, MD, PhD, a specialist in Clinical Immunology at Hospital Universitario de Canarias, Tenerife, Spain, has joined BioVaxys as a Scientific Adviser to support development ...
FDA Provides Necessary Guidance For BioVaxys To Begin Preparation Of Ind For Phase I/II Clinical Trials Of CoviDTH prnasia
July 23, 2021
BioVaxys is pleased to announce that the US Food and Drug Administration has provided its official Written Response to the Company's request for a Pre-IND Type B review of CoviDTH as a diagnostic for evaluating T-cell immune response to SARS-CoV-2.
BioVaxys Announces Non-Brokered Private Placement prnasia
June 29, 2021
BioVaxys Technology Corp. is pleased to announce a non-brokered private placement consisting of up to 9,090,909 units at a price of $0.22 per Unit for total gross proceeds of up to approximately $2,000,000.
BioVaxys Receives Positive FDA Response For Pre-IND Review For CoviDTH Clinical Development prnewswire
June 15, 2021
BioVaxys Technology Corp. is pleased to announce today that FDA has reviewed its Pre-IND request for a Type B review of its CoviDTH program and has determined that a Written Response is sufficient to address the Company's questions regarding
BioVaxys And Bioproduction Partner Bio Elpida Begin Construction Of GMP Facility To Produce Clinical Supply For Planned Ovarian Cancer Vaccine Study prnasia
June 02, 2021
BioVaxys Technology Corp. is pleased to announce that its bioproduction partner Bio Elpida of Lyon, France, has initiated construction of a new Good Manufacturing Practice clean room facility needed for producing clinical supply of BVX-0918A ...
BioVaxys Announces Appointment of Policy Advisor prnasia
May 21, 2021
BioVaxys Technology Corp., a biotechnology company that is advancing viral and oncology vaccine platforms as well as immuno-diagnostic products, announced the appointment of Adam Coutts, PhD, as Policy Advisor.
BioVaxys Inks Deal with CDMO BioElpida contractpharma
May 06, 2021
BioVaxys Technology Corp. has signed a definitive exclusive bioproduction agreement with BioElpida S.A.S. of Lyon, France, to begin the clinical-grade bioproduction and aseptic packaging for BXV-0918A, BioVaxys' vaccine candidate for Stage III/Stage ...

Previous page 1 2 Next page